4ARTechnologies: Art & Technology innovator 4ARTechnologies completes its unique ecosystem with secure NFT marketplace for physical and digital artworks

(Zug, Switzerland): 4ARTechnologies today announced the 4ART marketplace for NFTs and digital art, the newest module in their all-in-one tool. The 4ART marketplace is the space to offer and trade NFTs with a few clicks and provides the safest way for creators and collectors to make transactions with ease.
With the new international marketplace for NFTs, the 4ARTechnologies ecosystem is now even more complete. To meet the high standards for security and transparency, only 4ART minted NFTs can be traded on the integrated marketplace.
"Our technology makes it both very easy and very safe for creators and collectors to trade non fungible tokens from secured artworks." - Kai Zeh, CTO 4ARTechnologies.
Features and benefits of the 4ART ecosystem include:
- Minting and securing the safest NFTs with a few clicks on any smart device
- Make transactions without the need of an extra crypto wallet
- Offer and trade directly on the integrated marketplace
- Experience and share physical and digital artworks together in the integrated VR showrooms
- Transfer to other marketplaces such as OpenSea, Nifty, Binance or Tezos
The marketplace will go online with NFT artworks by many 4ART artists, as well as international greats like Noah Becker. But also high end artworks were announced for the launch like the CryptoPunks.
The ability to mint and trade secure 4ART NFTs will be made available to selected artists in July, with full options and the complete marketplace becoming available to all users for the start of the next art market season in August 2021.
About 4ARTechnologies
With the goal of protecting the cultural heritage of art for future generations and bringing the global art market into the digital age, 4ARTechnologies is setting a new digital standard for the art world. The company combines the blockchain with its patented technology and offers all art world participants more transparency, security and efficiency.
Contacts
4ARTechnologies AG
Dino Lewkowicz
dino@4art-technologies.com
Mobile: +41 41 740 00 50
www.4art-technologies.com
Images

About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

